Lacosamide Anfarm

Lacosamide, the active ingredient in Lacosamide Anfarm, is a sodium channel blocker presented as a solution for injection for intravenous use. It is indicated for patients with partial‑onset (focal) seizures, including those refractory to other therapies, and is used as adjunctive treatment in broader epilepsy syndromes under medical supervision.

GNH USA supplies Lacosamide Anfarm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑controlled sourcing, regulatory adherence and reliable logistics for critical care settings, and provides consistent product availability across EU and global markets.

Lacosamide is a sodium channel blocker used in the management of focal seizure disorders.

Partial‑onset seizures: reduces the frequency of focal seizures. Adjunctive therapy in epilepsy: improves overall seizure control when added to existing antiepileptic regimens. Secondary generalized seizures: helps prevent progression of focal seizures to generalized seizures.

Lacosamide may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Dizziness - Nausea - Headache - Fatigue

Serious or Rare Side Effects: - Cardiac arrhythmia (including atrioventricular block) - Severe skin reactions (e.g., Stevens‑Johnson syndrome) - Hypersensitivity reactions (anaphylaxis)

When using Lacosamide, clinicians should consider several precautionary measures to ensure patient safety.

Cardiac monitoring: assess ECG for PR interval prolongation, especially in patients with pre‑existing conduction disorders. Renal impairment: adjust dosing or monitor plasma levels in patients with severe renal dysfunction. Hepatic impairment: use caution and consider dose adjustment in moderate to severe liver disease. Concomitant CNS depressants: monitor for additive sedation or respiratory depression. Pregnancy and lactation: safety data are limited; weigh potential benefits against unknown risks. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Lacosamide can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Class I antiarrhythmics: may exacerbate cardiac conduction effects. - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase lacosamide plasma concentrations. - Strong CYP3A4 inducers (e.g., rifampin): reduce lacosamide exposure.

Moderate Interactions (Monitor Closely): - Other antiepileptic drugs (e.g., carbamazepine, phenytoin): may alter seizure control. - Oral contraceptives: lacosamide may reduce hormonal efficacy, requiring additional contraceptive measures.